Christine Blank, Contributing Editor

Patients with atrial fibrillation who have had cancer are less likely to see a cardiologist and less likely to fill anticoagulant prescriptions.

A new study fills in information gaps on NOAC use in patients age 80 and over.

More telepharmacies are opening and it appears that they are creating jobs. 

The agency is exploring ways to increase vital medication access.

Small Doses is pharmacy news in a way that works for your busy lifestyle

Amazon's acquiring of PillPack made headlines, but it might not make as many ripples as you would think.

An ASHP survey found that more pharmacists are being hired due to expanding roles.

A multistate antitrust investigation into generic drug pricing has expanded further.

The FDA is promoting generic competition and issuing new REMS guidance.

How becoming a certified diabetes educator can help improve lives.

Oral anticoagulants are associated with a significant reduction in dementia risk for atrial fibrillation patients.

A new resource for patients with deep vein thrombosis aims to educate about interventional therapies.

Three pharmacists were caught trying to access the deceased star’s records just days after his death.

A change in reimbursement policy for biosimilar drugs could save CMS billions.

The FDA has issued draft guidances that should ease the way for more generic drugs.

Dual antithrombotic therapy using dabigatran significantly reduces risk of bleeding compared to triple therapy using warfarin.

The risk of intraocular bleeding was reduced by one-fifth when using newer anticoagulants versus warfarin in a new study.

A California bill aimed at curbing drug prices is about to be signed, despite concerns it will raise generic drug prices.

CVS Health executives are pleased that a lawsuit alleging collusion with PBMS on generic drug costs has been withdrawn.

Rivaroxaban (Xarelto, Janssen/ Bayer) has been found to significantly reduce the risk of strokes and heart attacks in patients with artery disease.

Senate passes FDARA overwhelmingly, ahead of September deadline.

Generic drugs make up 90% of prescriptions.

Savings from generic and biosimilar drugs are making PBMs and pharmacies, as well as patients, happy.

Pharmacy chains are forcing lower generic prices for their customers.

Two recent generic cholesterol-lowering drugs are helping reduce health-care costs.

FDA will shorten the review periods for priority generic drugs by two months.

High court ruling should make biosimilars available faster.

Patients are less like to buy a requested brand name prescription than a generic one.